Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-IE plus pegfilgrastim for relapsed or refractory CD20-positive diffuse large B-cell lymphoma
ACTRN12606000373572Phase 4Recruiting
- Sponsor
- Roche
- Start
- May 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab, ifosfamide, etoposide and pegfilgrastim in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Primary endpoint: Overall treatment response. Started May 2006; status: recruiting.
02
Drugs
rituximabifosfamideetoposidepegfilgrastim
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ACTRN12606000373572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000373572.